RxDoctor Payments Data

Benjamin Potkin, MD

Cardiovascular Disease · Santa Cruz, CANPI 1740335090

Payments from drug & device makers

$34,687in general payments, 2019–2025

Across 777 payments — averaging $44.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$20K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Amgen$2K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Abbott$976
  • plus $8K from 23 others

What the payments were for

  • Consulting fees$3001%
  • Speaking & faculty fees$18,41553%
  • Food & beverage$15,37944%
  • Education$5932%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,687 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$2,003,732
Medicare patients
1,585
Services billed
14,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban961$1,106,435
XareltoRivaroxaban254$293,964
Repatha SureclickEvolocumab185$204,021
MultaqDronedarone Hcl104$125,023
EntrestoSacubitril/Valsartan73$100,165
JardianceEmpagliflozin73$87,560
OzempicSemaglutide68$72,111
FarxigaDapagliflozin Propanediol57$52,644
VerquvoVericiguat20$36,669
BrilintaTicagrelor21$22,219
Valsartan514$19,318
Ranolazine ErRanolazine146$15,603
Diltiazem 24hr Er (Cd)Diltiazem Hcl428$15,511
Metoprolol Succinate1,108$14,973
Praluent PenAlirocumab17$12,292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$786$1,106,435961 claims
Johnson & JohnsonXarelto$20,225$293,964254 claims
Sanofi-aventis U.S. LLCMultaq$166$125,023104 claims
NovartisEntresto$899$100,16573 claims
Boehringer IngelheimJardiance$763$87,56073 claims
AstraZenecaFarxiga, Brilinta$1,045$74,86478 claims
Novo NordiskOzempic$1,160$72,11168 claims
MerckVerquvo, Januvia$922$42,75032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Santa Cruz

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →